Combined PET/CT with Iodine-124 in Diagnosis of Mediastinal Micrometastases in Thyroid Carcinoma

L Freudenberg, G Antoch, R Görges, E Knust, T Beyer, J Debatin

Abstract

Iodine-124 PET is a useful 3-dimensional imaging technique for diagnosis and management of thyroid diseases. The difficulty in interpretation of the PET scans with highly selective tracers like iodine-124, is the lack of identifiable anatomical structures, so an accurate anatomical localization of foci presenting abnormal uptake is problematic. Consequently, a combined PET/CT scanner can resolve these difficulties by co-registering PET and CT data in a single session allowing a correlation of functional and morphologic imaging.

A case is presented where iodine-124 produced by a clinical cyclotron was used with a combined PET/CT scanner for clinical staging of a patient with thyroid carcinoma.

IODINE-124 PET/CT

24 hours after the oral administration of 85 MBq of the positron-emitting radionuclide [iodine-124]-sodium-iodide \(^\text{[1]}\) images on a combined PET/CT system were acquired (biograph, Siemens Medical Solutions Erlangen, Germany manufactured by CPS, Knoxville, USA). Projections from head to pelvis were obtained. The biograph consists of a single slice spiral CT (Somaton Emotion) and a dedicated full-ring PET scanner (ECAT HR+). The CT data are also used for PET attenuation correction in a 3D mode \([2,3]\). The PET scan alone showed pathologically increased tracer uptake in two cervically or mediastinal foci (Fig. 1, left).

An accurate anatomical localization of these foci was not completely possible as the tracer is highly specific. The CT scan alone showed no pathology. Image fusion of PET and the co-registered CT enabled to attribute the pathological tracer uptake to an area close to the aorta representing mediastinal micrometastases.

IODINE-131 SCAN

Iodine-131 Scan; Eight days after the oral administration of the therapeutic dose of 3,000 MBq Iodine-131 a whole body scan was acquired (Bodyscan, Siemens Erlangen, Germany) using a high energy collimator. Pathological tracer uptake was documented cervically and mediastinally.
**DISCUSSION**

Patients with well-differentiated thyroid cancer (WDTC) regularly have an excellent prognosis. However, staging is crucial for appropriate surgical treatment, radioiodine therapy, and, in advanced disease, external beam radiotherapy [1]. Besides whole-body iodine-131 scintigraphy, ultrasonography, fluorine-18 fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is an established diagnostic tool in the follow-up of thyroidec­tomized patients with WDTC [4,5,7]. Another positron emitter suitable for PET imaging is iodine-124 with a half-life of 4.2 days. It has not been widely used because of a complex decay scheme including several high energy gamma rays [6]. This 3-dimensional imaging technique has been shown to be an useful imaging technique for diagnosis and management of thyroid diseases [11]. However, the difficulty in interpretation of the PET scans with highly sensitive tracers like iodine-124, is the lack of identifiable anatomical structures [2]. The low anatomical resolution of the presented PET scan is insufficient for an accurate anatomical localization of foci with abnormal uptake (Fig. 1, right). In our case, the use of a combined PET/CT system provided accurately fused PET and CT images in a single session [2-3]. Fused images revealed mediastinal micrometastases of the thyroid carcinoma. Accurate metabolic and anatomical staging was therefore accomplished. Compared to iodine-131 whole body scan, iodine-124 PET/CT has shown to be superior in exact localization of metastases.

**ADDRESS FOR CORRESPONDENCE**

Dr. med. L. S. Freudenberg, M.A. Clinic and Polyclinic for Nuclear Medicine University of Essen Hufelandstrasse 55 D-45122 Essen Germany Tel: +49 / 201 723-2032 Fax: +49 / 201 723-5964 Email: lutz.freudenberg@uni-essen.de

**References**

8. van Tol KM, Jager PL, Dullaart RP, Links TP. Follow-up in patients with differentiated thyroid carcinoma with positive 18F-fluoro-2-deoxy-D-glucose-positron emission tomography results, elevated thyroglobulin levels, and negative high-dose 131I posttreatment whole body scans. J Clin Endocrinol Metab 2000; 85:2082-2083.
thyroid using 124I. J Clin Endocrinol Metab 1986; 63:918-927.

Author Information

L S Freudenberg, MD
Clinic and Policlinic for Nuclear Medicine, University of Essen

G Antoch, MD
Department of Radiology, Clinic and Policlinic for Nuclear Medicine, University of Essen

R Görges, MD
Clinic and Policlinic for Nuclear Medicine, University of Essen

EJ Knust
Clinic and Policlinic for Nuclear Medicine, University of Essen

T Beyer
CTI-PET Systems

JF Debatin, MD
Department of Radiology, University of Essen